title: A patient with hyper-IgD syndrome responding to anti-TNF treatment.
abstract: The hyperimmunoglobulinemia D periodic fever syndrome (HIDS) is caused by recessive mutations in the mevalonate kinase gene, which encodes an enzyme involved in cholesterol and nonsterol isoprenoid biosynthesis. The pathogenesis and treatment remains unclear. We describe a 6-year-old Turkish girl with severe disease. Her clinical features were accompanied with very high acute-phase reactants including a very high serum amyloid A level. The patient responded well to anti-tumor necrosis factor treatment. Our findings support the use of this anti-cytokine treatment in HIDS.
authors.affiliation: Pediatric Nephrology and Rheumatology Unit, Department of Pediatrics, Hacettepe University Faculty of Medicine, 06100 Sihhiye, Ankara, Turkey. dottore_erkan@yahoo.com
authors.forename: Erkan
authors.initials: E
authors.lastname: Demirkaya
authors.forename: M Kazim
authors.initials: MK
authors.lastname: Caglar
authors.forename: Hans R
authors.initials: HR
authors.lastname: Waterham
authors.forename: Rezan
authors.initials: R
authors.lastname: Topaloglu
authors.forename: Seza
authors.initials: S
authors.lastname: Ozen
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology; D002648:Child; D005260:Female; D005334:Fever; D006801:Humans; D006942:Hypergammaglobulinemia / Q000188:drug therapy*; D007072:Immunoglobulin D / Q000737:chemistry; D009154:Mutation; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics; D000685:Serum Amyloid A Protein / Q000096:biosynthesis; D019821:Simvastatin / Q000494:pharmacology; D013577:Syndrome; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*; D014421:Turkey
chemical_list: D000924:Anticholesteremic Agents; D007072:Immunoglobulin D; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D019821:Simvastatin; D017853:Phosphotransferases (Alcohol Group Acceptor); C021796:mevalonate kinase